Several studies have revealed that the macrophage chemoattractant protein-1 (MCP-1) (33) and hepatocyte growth factor (HGF) (34) are able to promote MSC migration into malignant gliomas, confirming the potential applications of genetically modified MSCs for cancer gene therapy. Here, CCL2 is linked to cancer.